IceCure Medical Ltd. (NASDAQ:ICCM – Free Report) – Equities research analysts at Brookline Capital Markets increased their Q2 2026 earnings per share (EPS) estimates for shares of IceCure Medical in a research note issued on Monday, June 22nd. Brookline Capital Markets analyst K. Dolliver now anticipates that the company will post earnings per share of ($0.95) for the quarter, up from their previous estimate of ($1.80). The consensus estimate for IceCure Medical’s current full-year earnings is ($4.50) per share. Brookline Capital Markets also issued estimates for IceCure Medical’s Q3 2026 earnings at ($0.56) EPS, Q4 2026 earnings at ($0.65) EPS, FY2026 earnings at ($3.51) EPS, FY2027 earnings at ($2.02) EPS, FY2028 earnings at ($1.26) EPS, FY2029 earnings at $0.88 EPS and FY2030 earnings at $3.21 EPS.
Several other brokerages have also recently issued reports on ICCM. Alliance Global Partners assumed coverage on shares of IceCure Medical in a research note on Monday, May 4th. They issued a “buy” rating on the stock. Maxim Group lowered their target price on shares of IceCure Medical from $90.00 to $30.00 and set a “buy” rating on the stock in a report on Thursday, May 14th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of IceCure Medical in a research note on Tuesday, April 21st. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $62.70.
IceCure Medical Price Performance
Shares of NASDAQ ICCM opened at $9.30 on Thursday. The stock has a fifty day moving average price of $6.85 and a 200 day moving average price of $13.93. IceCure Medical has a 1-year low of $2.12 and a 1-year high of $42.00. The company has a market cap of $26.13 million, a PE ratio of -1.29 and a beta of 0.40.
IceCure Medical (NASDAQ:ICCM – Get Free Report) last released its earnings results on Tuesday, May 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.03). IceCure Medical had a negative net margin of 441.60% and a negative return on equity of 211.73%. The company had revenue of $0.91 million during the quarter, compared to analyst estimates of $1.34 million.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of ICCM. Jane Street Group LLC acquired a new stake in IceCure Medical in the fourth quarter valued at $67,000. Virtu Financial LLC purchased a new stake in shares of IceCure Medical during the 4th quarter worth $39,000. Finally, Concurrent Investment Advisors LLC acquired a new position in shares of IceCure Medical during the 4th quarter worth $48,000. Hedge funds and other institutional investors own 0.62% of the company’s stock.
About IceCure Medical
IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.
Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.
Read More
- Five stocks we like better than IceCure Medical
- Washington’s Quantum Push Puts IBM and IonQ on the Throne
- FedEx’s Earnings Drop May Be Missing the Bigger Freight Story
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.
